Antigenicity and Epitope Specificity of ZnT8 Autoantibodies in Type 1 Diabetes

Scandinavian Journal of Immunology

Volumn 77, Issue 1, 2013, Pages 21-29

  Skarstrand H ^a   Lernmark, A ^a   Vaziri Sani, F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CARRIER PROTEIN; EPITOPE; GLUTAMINE; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 PROTEIN;

ADOLESCENT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; RADIOASSAY; RADIOBINDING ASSAY; RNA TRANSLATION; SCHOOL CHILD;

ADOLESCENT; ANIMALS; ANTIBODY AFFINITY; AUTOANTIBODIES; AUTOANTIGENS; CATION TRANSPORT PROTEINS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84871682813     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12008     Document Type: Article

References (33)

1. Kulmala P, Savola K, Petersen JS et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998;101:327-36.
2. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity 2008;41:11-18.
3. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011;57:168-75.
4. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-5.
5. Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW. Identification of a major humoral epitope in Slc30A8 (ZnT8). Ann N Y Acad Sci 2008;1150:252-5.
6. Wenzlau JM, Moua O, Sarkar SA, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008;1150:256-9.
7. Vaziri-Sani F, Oak S, Radtke J, et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 2010;43:598-606.
8. Vermeulen I, Weets I, Costa O, et al. An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia 2012;55:413-20.
9. Nielsen LB, Vaziri-Sani F, Porksen S, et al. Relationship between ZnT8Ab, the SLC30A8 gene and disease progression in children with newly diagnosed type 1 diabetes. Autoimmunity 2011;44:616-23.
10. Andersen ML, Vaziri-Sani F, Delli A et al. Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes. Pediatr Diabetes 2012;13:454-62.
11. Kawasaki E, Nakamura K, Kuriya G, et al. Zinc transporter 8 autoantibodies in fulminant, acute-onset, and slow-onset patients with type 1 diabetes. Diabetes Metab Res Rev 2011;27:895-8.
12. Yang L, Luo S, Huang G, et al. The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab Res Rev 2010;26:579-84.
13. Wenzlau JM, Liu Y, Yu L, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-7.
14. Andersson C, Larsson K, Vaziri-Sani F et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011;44:394-405.
15. Delli AJ, Vaziri-Sani F, Lindblad B et al. Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and swedish patients with newly diagnosed type 1 diabetes in the better diabetes diagnosis study. Diabetes 2012;61:2556-64.
16. Vaziri-Sani F, Delli AJ, Elding-Larsson H, et al. A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol Methods 2011;371:25-37.
17. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-5.
18. Gohlke H, Ferrari U, Koczwara K, Bonifacio E, Illig T, Ziegler AG. SLC30A8 (ZnT8) polymorphism is associated with young age at type 1 diabetes onset. Rev Diabet Stud 2008;5:25-7.
19. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-54.
20. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52:1881-8.
21. Brorsson C, Vaziri-Sani F, Bergholdt R, et al. Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity 2011;44:107-14.
22. Wenzlau JM, Frisch LM, Hutton JC, Davidson HW. Mapping of conformational autoantibody epitopes in ZNT8. Diabetes Metab Res Rev 2011;27:883-6.
23. Schlosser M, Banga JP, Madec AM, et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005;48:922-30.
24. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005;54 (Suppl 2):S52-61.
25. Atar D, Dyrberg T, Michelsen B, et al. Site-specific antibodies distinguish single amino acid substitutions in position 57 in HLA-DQ beta-chain alleles associated with insulin-dependent diabetes. J Immunol 1989;143:533-8.
26. Petersen JS, Atar D, Karlsen A, Kofod H, Dyrberg T. Characterization of the fine specificity of peptide antibodies to HLA-DQ beta-chain molecules. Biomed Biochim Acta 1990;49:1223-32.
27. Petersen JS, Dyrberg T. Production of epitope specific monoclonal IgG antibodies to HLA class II molecules by combining in vivo and in vitro immunization. J Immunol Methods 1992;151:15-26.
28. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-97.
29. Andersson C, Vaziri-Sani F, Delli A et al. Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes 2012; doi: 10.1111/j.1399-5448.2012.00916.x. [Epub ahead of print].
30. Hagopian WA, Erlich H, Lernmark A, et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 2011;12:733-43.
31. Larsson HE, Lynch K, Lernmark B, et al. Diabetes-associated HLA genotypes affect birthweight in the general population. Diabetologia 2005;48:1484-91.
32. Steck AK, Zhang W, Bugawan TL, et al. Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR, DQ genotypes? Diabetes 2009;58:1028-33.
33. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004;27:2695-700.